<DOC>
	<DOCNO>NCT00005978</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Giving drug different way may kill tumor cell . Radiation therapy use high-energy x-rays damage tumor cell . Peripheral stem cell bone marrow transplantation may able replace immune cell destroy chemotherapy radiation therapy . PURPOSE : This phase I trial study side effect best dose combination chemotherapy give stem cell transplant radiation therapy treat patient neuroblastoma respond previous treatment .</brief_summary>
	<brief_title>N99-01 : Combination Chemotherapy , Radiation Therapy , Stem Cell Transplantation Treating Patients With Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerated dose toxic effect iodine I 131 metaiodobenzylguanidine ( 131 I-MIBG ) plus ablative dos carboplatin etoposide administer fixed-dose melphalan follow autologous hematopoietic stem cell transplantation patient refractory residual high-risk neuroblastoma . - Determine number day blood count recover patient receive treatment regimen . - Determine response rate treatment regimen patient . - Determine tumor dosimetry 131 I-MIBG patient measurable soft tissue lesion . OUTLINE : This dose-escalation study iodine I 131 metaiodobenzylguanidine ( 131 I-MIBG ) , carboplatin , etoposide . Patients stratify accord glomerular filtration rate ( least 100 mL/min vs 60-99 mL/min ) . Patients undergo peripheral blood stem cell harvest bone marrow harvest least 2 week prior treatment 131 I-MIBG . Patients receive 131 I-MIBG IV 120 minute day -21 ; melphalan IV day -7 -5 ; carboplatin etoposide IV continuously 96 hour day -7 -4 ; autologous hematopoietic stem cell transplantation IV 15-30 minute day 0 ; filgrastim ( G-CSF ) subcutaneously IV start day 0 continue blood count recover . Radiotherapy administer primary tumor site metastatic site twice daily 7 consecutive day within 6 week transplantation blood count recover . Cohorts 3-6 patient receive escalate dos 131 I-MIBG , carboplatin , etoposide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Patients follow day 84 , 2 month later complete response and/or partial response . Patients continue therapy protocol follow start new therapy . All patient follow life delay toxic effect relate study therapy , secondary malignancy , disease status , survival . PROJECTED ACCRUAL : A total 30-60 patient ( 15-30 per stratum ) accrue study within 2-3 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma evidence one following : Histological confirmation Demonstrates clump tumor cell bone marrow elevate urinary catecholamine metabolite Highrisk refractory residual disease Poorly respond disease , meet 1 follow criterion : Stable disease partial response least 12 week induction therapy Bone marrow contain great 100 tumor cell per 100,000 normal cell 12 week induction therapy Progressive disease therapy At least 1 prior positive iodine I 131 metaiodobenzylguanidine ( 131 IMIBG ) scan since diagnosis meet disease status criterion PATIENT CHARACTERISTICS : Age : 1 21 ( 1 20 diagnosis ) Performance status : ECOG 02 Life expectancy : At least 2 month Hematopoietic : Absolute neutrophil count least 500/mm^3 Platelet count least 20,000/mm^3 ( transfusion allow ) Hemoglobin least 8 g/dL ( transfusion allow ) Hepatic : Bilirubin normal AST/ALT great 3 time normal No active hepatitis ( HIVpositive patient ) Renal : Glomerular filtration rate creatinine clearance least 60 mL/min Creatinine le 1.5 time normal age Cardiovascular : Ejection fraction least 55 % OR Fractional shorten least 30 % Pulmonary : No dyspnea rest exercise intolerance No requirement supplemental oxygen No active pneumonia ( HIVpositive patient ) Other : No disease major organ system would preclude study participation No active health problem ( HIVpositive patient ) No active infection require intravenous antiviral , antibiotic , antifungal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 3 week since prior biologic therapy recover Chemotherapy : At least 3 week since prior chemotherapy recover No 100 mg/m^2 total dose prior melphalan Endocrine therapy : Not specify Radiotherapy : No prior total body , whole abdominal , whole liver irradiation No prior therapy 131 IMIBG At least 2 week since prior radiotherapy ( 6 month prior radiotherapy craniospinal whole lung field great 50 % bone marrow space ) recover Surgery : Prior surgical resection allow Recovered prior surgery Other : No prior myeloablative therapy Prior submyeloablative therapy peripheral blood stem cell support allow No concurrent antiretrovirals HIVpositive patient Concurrent prolong antifungal allowed culture biopsy negative suspect residual radiographic lesion No medication may preclude uptake 131 IMIBG 1 week prior 2 week administration study drug No concurrent hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>stage 4S neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>